X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ACTAVIS
Dec-14
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs80918,935-   
Low Rs50411,550-   
Sales per share (Unadj.) Rs281.13,409.7-  
Earnings per share (Unadj.) Rs41.4-425.5-  
Cash flow per share (Unadj.) Rs50.9312.8-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.47,395.5-  
Shares outstanding (eoy) m585.88265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.5 52.3%   
Avg P/E ratio x15.9-35.8 -44.3%  
P/CF ratio (eoy) x12.948.7 26.5%  
Price / Book Value ratio x3.32.1 159.8%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6304,052,964 9.5%   
No. of employees `00017.321.6 80.2%   
Total wages/salary Rs m21,3080-   
Avg. sales/employee Rs Th9,500.741,973.8 22.6%   
Avg. wages/employee Rs Th1,229.40-   
Avg. net profit/employee Rs Th1,397.9-5,237.9 -26.7%   
INCOME DATA
Net Sales Rs m164,666906,633 18.2%  
Other income Rs m1,020-2,263 -45.1%   
Total revenues Rs m165,686904,371 18.3%   
Gross profit Rs m37,718116,470 32.4%  
Depreciation Rs m5,580196,319 2.8%   
Interest Rs m77728,597 2.7%   
Profit before tax Rs m32,380-110,709 -29.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,121 0.0%   
Tax Rs m8,183-5,692 -143.8%   
Profit after tax Rs m24,229-113,138 -21.4%  
Gross profit margin %22.912.8 178.3%  
Effective tax rate %25.35.1 491.5%   
Net profit margin %14.7-12.5 -117.9%  
BALANCE SHEET DATA
Current assets Rs m121,878477,680 25.5%   
Current liabilities Rs m86,806348,369 24.9%   
Net working cap to sales %21.314.3 149.3%  
Current ratio x1.41.4 102.4%  
Inventory Days Days13058 223.9%  
Debtors Days Days6866 103.1%  
Net fixed assets Rs m81,037110,709 73.2%   
Share capital Rs m5860-   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,8041,966,455 5.9%   
Long term debt Rs m4,5121,030,461 0.4%   
Total assets Rs m211,0523,603,864 5.9%  
Interest coverage x42.7-2.9 -1,485.8%   
Debt to equity ratio x00.5 7.4%  
Sales to assets ratio x0.80.3 310.1%   
Return on assets %11.8-2.3 -505.1%  
Return on equity %20.7-5.8 -360.5%  
Return on capital %27.4-3.0 -908.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,548155,687 12.6%  
From Investments Rs m-19,570-372,773 5.2%  
From Financial Activity Rs m8,642209,445 4.1%  
Net Cashflow Rs m8,922-7,642 -116.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.41 Rs / USD

Compare AUROBINDO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: SHASUN PHARMA  NATCO PHARMA  GSK PHARMA  PFIZER  TTK HEALTHCARE  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TORRENT PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS